News & Media

Follow our news


News

2024-03-11

PolTREG’s state-of-the-art manufacturing facility has received approval to produce cellulartherapies from the Chief Pharmaceutical Inspectorate in Poland.

See

2024-02-21

PolTREG appoints Dan Shelly, PhD, MBA as Chief Business Development Officer to help it build partnerships across industry and deliver milestones

See

2024-02-07

Global institutional investors and investment funds hold over 25% of PolTREG’s shares.

See

2024-01-30

Prof. Piotr Trzonkowski co-authors peer-reviewed article showing scientific progress in T-regautoimmune therapy

See

2024-01-16

PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes

See

2024-01-15

The J.P. Morgan Healthcare Conference 2024 is already behind us!

See

2024-01-02

PolTREG at J.P. Morgan Healthcare Conference

See

Materials
for Media

PolTREG logo

Download

PolTREG Leadership team

Download

Contact for Media

ir@poltreg.com